Once you start taking Anamorelin, do you need to take it for life?

Anamorelin is a peptidomimetic growth hormone secretion promoter, mainly used to improve symptoms such as weight loss, loss of appetite and muscle loss in patients with cancer-related cachexia (Cancer Cachexia). It induces appetite enhancement by stimulating gastrin receptors (ghrelin receptor), while increasing levels of growth hormone (GH) and insulin-like growth factor -1 (IGF-1) in the body, thereby promoting muscle synthesis and weight gain. However, whether it is necessary to take anamorelin for life depends on the specific condition and treatment goals. Not all patients must take it for a long time or even for life.

From the perspective of clinical indications and pharmacological mechanisms, anamorelin is used for the supportive treatment of cancer cachexia and is not a radical drug for the tumor itself. Its goal is to relieve the symptoms of cachexia and improve quality of life. Therefore, once the patient's condition is under control or cachexia symptoms are significantly improved, gradual discontinuation of the drug or dose reduction can be considered after physician evaluation. Especially when the cancer is in remission or stable, there is no need for long-term dependence on anamorelin.

From the perspective of safety and long-term medication risks, current clinical studies are mostly focused on the use of anamorelin for a course of about 12 weeks. There is still a lack of large-scale data support for the safety of long-term or lifelong use. Some patients may experience minor adverse reactions during use, such as hyperglycemia, edema, headache or fatigue. Whether long-term use will increase cardiovascular burden still requires more research. Therefore, when doctors recommend continued use, they often weigh the pros and cons and make medication adjustments based on the dynamics of the disease, rather than one-size-fits-all lifelong use.

In actual clinical management, the use of anamorelin requires individualized adjustment. For patients who still have active tumors and severe symptoms of cachexia, anamorelin may need to be continued for a period of time to maintain nutritional status. However, for patients whose symptoms are relieved and whose nutrition has improved significantly, phased drug withdrawal and observation can be considered. If the patient suffers from loss of appetite or weight loss again after stopping the drug, anamorelin can be started again. Therefore, continued use should be decided by the physician based on disease assessment, patient physical condition, and quality of life goals.

Reference materials:https://www.drugs.com/